JP2020516681A - がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ - Google Patents

がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ Download PDF

Info

Publication number
JP2020516681A
JP2020516681A JP2020504440A JP2020504440A JP2020516681A JP 2020516681 A JP2020516681 A JP 2020516681A JP 2020504440 A JP2020504440 A JP 2020504440A JP 2020504440 A JP2020504440 A JP 2020504440A JP 2020516681 A JP2020516681 A JP 2020516681A
Authority
JP
Japan
Prior art keywords
peptide
cells
cancer
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020504440A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516681A5 (enExample
Inventor
マルコ，モレノ ディ
マルコ，モレノ ディ
ハエン，セバスチャン
コバレフスキ，ダニエル
レッフラー，マルクス
ネルデ，アニカ
ランメンゼー，ハンスーゲオルグ
ステヴァノヴィッチ，シュテファン
トラウトヴァイン，ニコ
サラ ヴァルツ，ユリアーネ
サラ ヴァルツ，ユリアーネ
Original Assignee
イマティクス バイオテクノロジーズ ゲーエムベーハー
イマティクス バイオテクノロジーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イマティクス バイオテクノロジーズ ゲーエムベーハー, イマティクス バイオテクノロジーズ ゲーエムベーハー filed Critical イマティクス バイオテクノロジーズ ゲーエムベーハー
Priority claimed from PCT/EP2018/059109 external-priority patent/WO2018189148A1/en
Publication of JP2020516681A publication Critical patent/JP2020516681A/ja
Publication of JP2020516681A5 publication Critical patent/JP2020516681A5/ja
Priority to JP2023067694A priority Critical patent/JP7551823B2/ja
Priority to JP2024151897A priority patent/JP2024174928A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
JP2020504440A 2017-04-10 2018-04-10 がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ Pending JP2020516681A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023067694A JP7551823B2 (ja) 2017-04-10 2023-04-18 がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ
JP2024151897A JP2024174928A (ja) 2017-04-10 2024-09-04 がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762483702P 2017-04-10 2017-04-10
US62/483,702 2017-04-10
DE102017107697 2017-04-10
DE102017107697.2 2017-04-10
PCT/EP2018/059109 WO2018189148A1 (en) 2017-04-10 2018-04-10 Peptides and combination thereof for use in the immunotherapy against cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023067694A Division JP7551823B2 (ja) 2017-04-10 2023-04-18 がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ

Publications (2)

Publication Number Publication Date
JP2020516681A true JP2020516681A (ja) 2020-06-11
JP2020516681A5 JP2020516681A5 (enExample) 2021-05-20

Family

ID=62116819

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020504440A Pending JP2020516681A (ja) 2017-04-10 2018-04-10 がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ
JP2023067694A Active JP7551823B2 (ja) 2017-04-10 2023-04-18 がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ
JP2024151897A Withdrawn JP2024174928A (ja) 2017-04-10 2024-09-04 がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023067694A Active JP7551823B2 (ja) 2017-04-10 2023-04-18 がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ
JP2024151897A Withdrawn JP2024174928A (ja) 2017-04-10 2024-09-04 がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ

Country Status (17)

Country Link
US (3) US20220332760A1 (enExample)
EP (2) EP3725327A3 (enExample)
JP (3) JP2020516681A (enExample)
KR (2) KR20240162609A (enExample)
CN (12) CN111548406A (enExample)
AU (2) AU2018251839B2 (enExample)
BR (1) BR112019020959A2 (enExample)
CA (1) CA3059644A1 (enExample)
CL (1) CL2019002880A1 (enExample)
CO (1) CO2019012077A2 (enExample)
CR (3) CR20210159A (enExample)
IL (1) IL269741A (enExample)
MA (2) MA51170A (enExample)
MX (1) MX2019012225A (enExample)
PE (1) PE20191711A1 (enExample)
PH (1) PH12019502308A1 (enExample)
SG (2) SG11201909153UA (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240162609A (ko) * 2017-04-10 2024-11-15 이매틱스 바이오테크놀로지스 게엠베하 암에 대한 면역요법에 사용하기 위한 펩티드 및 그 조합
PE20200693A1 (es) * 2017-07-07 2020-06-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluyendo el nsclc, el sclc y otros canceres
JP2023530235A (ja) * 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
CN111978375B (zh) * 2020-08-28 2022-10-04 深圳市乐土生物医药有限公司 具有细胞毒性t细胞诱导能力的蛋白质或多肽
CN112010960A (zh) * 2020-09-10 2020-12-01 热休(厦门)细胞生物科技有限公司 一种肿瘤抗原复合物体外致敏dc、t细胞获得肿瘤特异性杀伤细胞ctl及其制备方法
TWI827057B (zh) * 2021-05-18 2023-12-21 中國醫藥大學 疫苗、其用途及癌症疫苗混合物
CN114410638B (zh) * 2022-01-24 2023-04-14 郑州大学 一种核酸适配体及其在食管癌检测中的应用
CN117586344B (zh) * 2022-08-12 2025-07-25 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
CN116426532B (zh) * 2023-06-08 2023-09-12 时夕(广州)生物科技有限公司 一种靶向适配体及其应用
CN117552115B (zh) * 2024-01-12 2024-03-26 天津鲸鹏生物科技有限责任公司 用于诱导肿瘤特异性免疫响应的通用型抗原肽库及其应用
CN118480561A (zh) * 2024-05-30 2024-08-13 深圳大学总医院 一种aml1-eto融合基因产生的新抗原肽及其应用
CN119390773B (zh) * 2024-11-05 2025-08-12 绵阳市第三人民医院 一种具有双向调节肿瘤免疫微环境功能的多肽及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500059A (ja) * 1999-12-10 2004-01-08 エピミューン　インコーポレイテッド ペプチドおよび核酸組成物を使用する、癌胎児性抗原に対する細胞性免疫応答の誘導
JP2010502173A (ja) * 2005-09-05 2010-01-28 イマティクス バイオテクノロジーズ ゲーエムベーハー 無差別的にヒト白血球抗体（ｈｌａ）クラスｉｉ分子に結合する腫瘍関連ペプチド
JP2010104370A (ja) * 2002-09-06 2010-05-13 Mannkind Corp エピトープ配列
JP2016121097A (ja) * 2014-12-25 2016-07-07 有限会社イムノ 免疫応答を誘導するための薬剤
WO2016156202A1 (en) * 2015-03-27 2016-10-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
WO2016170139A1 (en) * 2015-04-24 2016-10-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ATE157100T1 (de) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL142216A0 (en) * 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
CA2383562A1 (en) * 1999-08-26 2001-03-01 Keith M. Skubitz Peptides capable of modulating the function of cd66 (ceacam) family members
AU785493B2 (en) 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CN101712721A (zh) 2000-06-05 2010-05-26 阿尔托生物科学有限公司 T细胞受体融合物及共轭物以及其使用方法
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
JP4572276B2 (ja) * 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
AU2013205381B2 (en) * 2002-03-19 2016-04-14 Celldex Therapeutics, Inc. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CN101260154A (zh) 2002-10-02 2008-09-10 霍夫曼-拉罗奇有限公司 新mhc ii相关肽
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
NZ570811A (en) 2002-11-09 2009-11-27 Immunocore Ltd T cell receptor display
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
EP1583548A4 (en) * 2002-12-10 2007-10-17 Epimmune Inc HLA-A1, A2 -A3, -A24, -B7 AND B44TUMOR ASSOCIATED ANTIGENPEPTIDES AND COMPOSITIONS
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
CN101265503A (zh) * 2003-03-10 2008-09-17 独立行政法人科学技术振兴机构 检测间充质干细胞的标记和采用该标记识别间充质干细胞的方法
EP2251039A3 (en) 2003-05-30 2010-12-08 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
CN101035561A (zh) * 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
DE602006010934D1 (de) 2005-04-20 2010-01-21 Hoffmann La Roche Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika
ES2367643T3 (es) * 2005-04-26 2011-11-07 Immatics Biotechnologies Gmbh Identificador de un epítopo de linfocitos t presentado por el antígeno hla-a2 y derivado de la proteína del receptor de laminina inmadura del antígeno oncofetal y usos de este.
WO2007011856A2 (en) * 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
CA2642994C (en) * 2006-02-24 2015-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic page-4 peptides and methods of use
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
JP5352586B2 (ja) * 2007-07-27 2013-11-27 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物
PL2183361T3 (pl) * 2007-07-27 2015-10-30 Immatics Biotechnologies Gmbh Innowacyjna immunoterapia przeciwko nowotworom mózgu
WO2009075883A2 (en) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
UA104572C2 (ru) * 2008-04-24 2014-02-25 Имматикс Байотекнолоджиз Гмбх Новые композиции опухолеассоциированных пептидов, которые связываются с молекулами i или ii класса лейкоцитарного антигена человека (hla) для разработки вакцин
US20110190157A1 (en) * 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
CA2816225A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US20190292535A1 (en) 2012-11-08 2019-09-26 Roche Diagnostics Operations, Inc. Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA45352A (fr) * 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
US10130693B2 (en) * 2015-08-28 2018-11-20 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
WO2018189148A1 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
KR20240162609A (ko) * 2017-04-10 2024-11-15 이매틱스 바이오테크놀로지스 게엠베하 암에 대한 면역요법에 사용하기 위한 펩티드 및 그 조합
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500059A (ja) * 1999-12-10 2004-01-08 エピミューン　インコーポレイテッド ペプチドおよび核酸組成物を使用する、癌胎児性抗原に対する細胞性免疫応答の誘導
JP2010104370A (ja) * 2002-09-06 2010-05-13 Mannkind Corp エピトープ配列
JP2010502173A (ja) * 2005-09-05 2010-01-28 イマティクス バイオテクノロジーズ ゲーエムベーハー 無差別的にヒト白血球抗体（ｈｌａ）クラスｉｉ分子に結合する腫瘍関連ペプチド
JP2016121097A (ja) * 2014-12-25 2016-07-07 有限会社イムノ 免疫応答を誘導するための薬剤
WO2016156202A1 (en) * 2015-03-27 2016-10-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
WO2016170139A1 (en) * 2015-04-24 2016-10-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers

Also Published As

Publication number Publication date
AU2018251839A1 (en) 2019-11-28
JP7551823B2 (ja) 2024-09-17
PE20191711A1 (es) 2019-11-28
KR20190137829A (ko) 2019-12-11
AU2018251839B2 (en) 2022-06-30
MA49122A (fr) 2021-03-24
CN111548404A (zh) 2020-08-18
US20230346837A1 (en) 2023-11-02
CO2019012077A2 (es) 2020-04-01
CN111533798A (zh) 2020-08-14
CR20210160A (es) 2021-04-26
CN111499715A (zh) 2020-08-07
CN110494157A (zh) 2019-11-22
US20220332760A1 (en) 2022-10-20
CN111533796A (zh) 2020-08-14
CN111499714A (zh) 2020-08-07
CA3059644A1 (en) 2018-10-18
JP2024174928A (ja) 2024-12-17
EP3725327A2 (en) 2020-10-21
CN111499716A (zh) 2020-08-07
KR20240162609A (ko) 2024-11-15
MA51170A (fr) 2020-10-21
SG11201909153UA (en) 2019-10-30
CN111528539A (zh) 2020-08-14
CN111548406A (zh) 2020-08-18
IL269741A (en) 2019-11-28
BR112019020959A2 (pt) 2020-05-05
SG10202107869QA (en) 2021-08-30
CR20210159A (es) 2021-05-21
EP3725327A3 (en) 2021-01-20
CN111533797A (zh) 2020-08-14
PH12019502308A1 (en) 2020-10-26
CR20190508A (es) 2020-01-08
EP3609530A1 (en) 2020-02-19
CN111548405A (zh) 2020-08-18
AU2022221503A1 (en) 2022-09-22
CN111647062A (zh) 2020-09-11
CL2019002880A1 (es) 2020-03-13
JP2023100687A (ja) 2023-07-19
MX2019012225A (es) 2019-12-09
US20220356208A1 (en) 2022-11-10
US11560405B2 (en) 2023-01-24

Similar Documents

Publication Publication Date Title
JP7551823B2 (ja) がんに対する免疫療法で使用するためのペプチドおよびその組み合わせ
US11542303B2 (en) Peptides and combination thereof for use in the immunotherapy against cancers
JP7229516B2 (ja) 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ
JP2019516663A (ja) 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤
JP2023113688A (ja) 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ
JP2020516313A (ja) 白血病およびその他のがんに対する免疫療法において使用するためのペプチドおよびペプチドの組み合わせ
JP2020530759A (ja) Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用
Class et al. Patent application title: PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS Inventors: Juliane Sarah Walz (Tuebingen, DE) Daniel Johannes Kowalewski (Tuebingen, DE) Daniel Johannes Kowalewski (Tuebingen, DE) Markus Loeffler (Ammerbuch, DE) Moreno Di Marco (Tuebingen, DE) Nico Trautwein (Stuttgart, DE) Annika Nelde (Tuebingen, DE) Stefan Stevanovic (Tuebingen, DE) Stefan Stevanovic (Tuebingen, DE) Hans Georg Rammensee (Tuebingen, DE) Hans Georg Rammensee (Tuebingen, DE) Sebastian Haen (Tuebingen, DE)
HK40029159A (en) Peptides and combination thereof for use in the immunotherapy against cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230418

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230428

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230707